Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$12.35 +0.9%	$10.59	$7.75 ▼ $19.93	$94.33M	0.49	25,855 shs	7,956 shs
CPIX Cumberland Pharmaceuticals	$5.27 +12.1%	$4.69	$1.04 ▼ $7.25	$73.61M	-0.35	860,236 shs	89,890 shs
NKTR Nektar Therapeutics	$0.71 +21.4%	$0.71	$0.43 ▼ $1.93	$133.03M	0.62	1.84 million shs	3.61 million shs
PRTK Paratek Pharmaceuticals	$2.23	$2.22	$1.29 ▼ $3.65	$127.82M	1.7	724,253 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	+1.40%	-12.60%	+36.01%	-5.94%	-7.84%
CPIX Cumberland Pharmaceuticals	+12.13%	+17.90%	+29.80%	+14.57%	+242.21%
NKTR Nektar Therapeutics	+21.42%	+4.02%	+15.72%	+7.78%	-59.39%
PRTK Paratek Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASMB Assembly Biosciences	3.6223 of 5 stars	3.3	3.0	0.0	4.7	1.8	0.8	0.0
CPIX Cumberland Pharmaceuticals	0.9199 of 5 stars	0.0	5.0	0.0	0.0	2.1	1.7	0.0
NKTR Nektar Therapeutics	3.9869 of 5 stars	3.5	3.0	0.0	4.2	2.1	2.5	0.0
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.67	Moderate Buy	$33.00	167.21% Upside
CPIX Cumberland Pharmaceuticals	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	3.00	Buy	$4.50	529.55% Upside
PRTK Paratek Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRTK, NKTR, ASMB, and CPIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
4/11/2025	NKTR Nektar Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$1.00 ➝ $2.00
3/25/2025	ASMB Assembly Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
3/24/2025	ASMB Assembly Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/14/2025	NKTR Nektar Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$6.00
3/13/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
3/13/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50 ➝ $6.50
2/25/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/25/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.50 ➝ $6.50

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$28.52M	3.31	N/A	N/A	$7.50 per share	1.65
CPIX Cumberland Pharmaceuticals	$37.87M	1.94	$0.61 per share	8.61	$1.96 per share	2.69
NKTR Nektar Therapeutics	$98.43M	1.35	N/A	N/A	$0.69 per share	1.04
PRTK Paratek Pharmaceuticals	$160.27M	0.80	N/A	N/A	($3.08) per share	-0.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$61.23M	-$6.23	N/A	N/A	N/A	-144.05%	-121.46%	-34.56%	5/14/2025 (Estimated)
CPIX Cumberland Pharmaceuticals	-$6.28M	-$0.25	N/A	∞	N/A	-29.54%	-9.50%	-3.19%	N/A
NKTR Nektar Therapeutics	-$276.06M	-$0.64	N/A	N/A	N/A	-180.70%	-173.28%	-46.31%	N/A
PRTK Paratek Pharmaceuticals	-$63.57M	-$1.10	N/A	∞	N/A	-35.44%	N/A	-40.05%	N/A

Latest PRTK, NKTR, ASMB, and CPIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	ASMB Assembly Biosciences	-$2.01	-$1.17	+$0.84	-$1.17	$7.41 million	$9.42 million
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$0.18	-$0.22	-$0.04	-$0.24	$15.61 million	$10.46 million
5/6/2025	Q1 2025	CPIX Cumberland Pharmaceuticals	N/A	$0.15	N/A	$0.08	N/A	N/A
3/20/2025	Q4 2024	ASMB Assembly Biosciences	-$1.75	-$1.57	+$0.18	-$1.57	$7.05 million	$7.36 million
3/12/2025	Q4 2024	NKTR Nektar Therapeutics	-$0.18	$0.15	+$0.33	$0.03	$36.65 million	$29.18 million
3/4/2025	Q4 2024	CPIX Cumberland Pharmaceuticals	N/A	-$0.03	N/A	-$0.14	N/A	$10.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CPIX Cumberland Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTK Paratek Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	2.36	2.36
CPIX Cumberland Pharmaceuticals	0.41	1.13	0.99
NKTR Nektar Therapeutics	N/A	4.24	4.24
PRTK Paratek Pharmaceuticals	N/A	0.52	0.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CPIX Cumberland Pharmaceuticals	15.51%
NKTR Nektar Therapeutics	75.88%
PRTK Paratek Pharmaceuticals	53.60%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	5.30%
CPIX Cumberland Pharmaceuticals	44.85%
NKTR Nektar Therapeutics	5.25%
PRTK Paratek Pharmaceuticals	8.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	100	7.64 million	6.03 million	Optionable
CPIX Cumberland Pharmaceuticals	80	13.97 million	7.96 million	Optionable
NKTR Nektar Therapeutics	220	186.10 million	177.62 million	Optionable
PRTK Paratek Pharmaceuticals	268	57.32 million	52.74 million	Optionable

PRTK, NKTR, ASMB, and CPIX Headlines

Recent News About These Companies

How a Bucks County firm's multiyear pursuit of a partner led to a potential $330M deal

April 11, 2025 | bizjournals.com

Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025

April 10, 2025 | globenewswire.com

Paratek acquires Optinose, rhinosinusitis spray Xhance in deal worth up to $330M

March 21, 2025 | fiercepharma.com

Paratek Pharmaceuticals to acquire Optinose in $330M transaction

March 21, 2025 | markets.businessinsider.com

Paratek boosts commercial portfolio in move to buy Optinose and its nasal spray

March 20, 2025 | endpts.com

Optinose Shares Surge Premarket on Takeover Deal With Paratek

March 20, 2025 | marketwatch.com

Paratek Pharmaceuticals Announces Completion of U.S. Onshoring Program, Making NUZYRA® (omadacycline) the Only Novel Antibiotic with Domestic Supply and Manufacturing Capabilities

November 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral ...

November 9, 2024 | eagletribune.com

Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease

November 8, 2024 | globenewswire.com

Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024

October 14, 2024 | globenewswire.com

Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens

July 31, 2024 | globenewswire.com

Paratek looks to bolster pneumonia antibiotic Nuzyra with win in post-marketing study

July 19, 2024 | fiercepharma.com

Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia

July 18, 2024 | globenewswire.com

Pharmaceuticals / Health Products Summary

April 4, 2024 | opensecrets.org

Paratek Reports Positive Data For Nuzyra As Post-exposure Prophylaxis Of Pulmonary Anthrax In NHPs

March 5, 2024 | markets.businessinsider.com

Mira Pharmaceuticals Stock (NASDAQ:MIRA) Dividends: History, Yield and Dates

February 24, 2024 | benzinga.com

Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

October 5, 2023 | finance.yahoo.com

PRTK Stock Sees Surge of Approximately 1.36% in Last Five Days

September 21, 2023 | knoxdaily.com

Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals

September 21, 2023 | finance.yahoo.com

Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

September 21, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTK, NKTR, ASMB, and CPIX Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$12.35 +0.11 (+0.90%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$12.34 -0.01 (-0.12%)

As of 05/12/2025 04:05 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Cumberland Pharmaceuticals NASDAQ:CPIX

$5.27 +0.57 (+12.13%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$5.44 +0.17 (+3.13%)

As of 07:35 AM Eastern

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Nektar Therapeutics NASDAQ:NKTR

$0.71 +0.13 (+21.42%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$0.74 +0.03 (+3.53%)

As of 05/12/2025 07:39 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Paratek Pharmaceuticals NASDAQ:PRTK

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time